Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIKOK-19 CAR-T Cell Therapy in R/R ALL and NHL
NCT04206943Phase 2Unknown
- Sponsor
- Acıbadem University
- Start
- Oct 2019
- Primary completion
- Jan 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of ISIKOK-19 in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Acıbadem University. Primary endpoint: Incidence of Adverse Events at 6 months. Status: unknown.
02
Drugs
ISIKOK-19
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04206943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04206943.